EOS is a small Taiwan-based distributor of consumer nutritional supplements. The company's core product is Bodywafer, a ginsenoside supplement — ginsenosides are the active compounds in ginseng, used in traditional Chinese medicine. EOS buys Bodywafer from its sole supplier, Wellhead Biological Technology, which holds patented ginsenoside extraction technology, and resells to channel partners (distributors and resellers) who then sell to end consumers, primarily in China, Singapore, and Malaysia. EOS also provides sales training to channel partners through seminars and webinars. Beyond supplements, EOS has sold water purifiers, though this line is minimal. EOS's business model is simple: buy finished goods from Wellhead and resell at a markup to channel partners. The company's customer and supplier concentration is extreme — a single customer accounted for 93% of FY23 sales, and a single supplier accounted for 88% of purchases. EOS does not manufacture anything and has no proprietary technology of its own; its value proposition rests entirely on access to Wellhead's patented products. Operating costs consistently exceed gross profit, resulting in persistent losses, and EOS has relied on shareholder loans to fund operations, drawing a going concern opinion from its auditors. EOS trades on the OTCQB under the ticker "EOSS," and its majority shareholder, Yu-Cheng Yang, controls approximately 65% of shares outstanding through Co-Innovation Group Limited.